Medtronic (NYSE: MDT) announced today that it entered into a strategic partnership with DASI Simulations.
The companies agreed to enhance access to technology from DASI, a leader in AI-driven predictive modeling and digital twin technology. They aim to optimize outcomes for patients undergoing transcatheter aortic valve replacement (TAVR) in the U.S.
Medtronic said the program marks a step forward in both its and DASI’s mission to deliver innovative, patient-specific care. The medtech giant says integrating advanced AI-based predictive modeling and digital twin technology into the TAVR workflow can give clinicians access to independent and device-agnostic actionable insights. This would, in turn, support precise, individualized treatment decisions for patients with aortic stenosis.
One of the largest medtech companies in the world, Medtronic develops a range of TAVR offerings, including its Evolut portfolio of valves.
(MDO’s Medtech Big 100 Special Report takes a deep look at the world’s 100 largest medical device companies, including Medtronic. Visit here for a free download.)
Dr. Matthew Summers, an interventional cardiologist at Sentara Heart Hospital, said effective pre-case planning is “essential” in TAVR. Summers said DASI’s predictive modeling allows cardiologists to better visualize anatomy, anticipate risks and tailor decisions to each patient.
“Partnering with Medtronic accelerates our mission to bring scalable, AI-powered planning tools to structural heart programs nationwide,” said Teri Sirset, founder, president, and CEO of DASI Simulations. “Together, we’re demonstrating how predictive modeling can drive operational efficiency, support clinical decision-making, and elevate the standard of care. This collaboration reflects the growing demand for data-driven solutions that empower heart teams to deliver more confident, personalized treatment decisions.”
More about the DASI platform and the partnership with Medtronic
DASI’s FDA-cleared platform utilizes real patient computerized tomography (CT) anatomies and retrospective outcomes. It simulates multiple transcatheter heart valve (THV) scenarios.
Using data-driven reports, the platform helps mitigate human error, predict complications and optimize long-term patient management.
“The future of TAVR lies in delivering patient-specific, data-driven care that spans the full patient journey, from therapy awareness and innovation to procedural excellence and options for future intervention,” said Jorie Soskin, VP and GM of the Structural Heart business within the Cardiovascular portfolio at Medtronic. “Our partnership highlights our commitment to lead this future, allowing heart teams to utilize AI driven pre-procedural planning to enhance patient outcomes, streamline workflow, and support patient-specific valve selection.”
Medtronic said participating sites in the partnership have access to both its Structureal Heart team and DASI’s team. The companies aim to demonstrate the clinical and operational value of simulation-based planning in TAVR care. They hope to enable device agnostic, patient-specific treatment.
“We are entering a new era in structural heart care, guided by predictive AI models that help the physician determine the best treatment personalized for each patient, rather than relying on statistical norms,” said Lakshmi Dasi, founder and CTO at DASI Simulations. “This shift to precision medicine will transform how we treat structural heart diseases. DASI is the pioneer for AI-based predictive modeling for TAVR, and our platform is designed to support unbiased and device agnostic decision-making with the patient at the center that will ultimately support more confident, personalized interventions.”
